IL239778A0 - Pharmaceutical preparations with controlled release of lorazepam - Google Patents

Pharmaceutical preparations with controlled release of lorazepam

Info

Publication number
IL239778A0
IL239778A0 IL239778A IL23977815A IL239778A0 IL 239778 A0 IL239778 A0 IL 239778A0 IL 239778 A IL239778 A IL 239778A IL 23977815 A IL23977815 A IL 23977815A IL 239778 A0 IL239778 A0 IL 239778A0
Authority
IL
Israel
Prior art keywords
lorazepam
controlled release
release formulations
formulations
controlled
Prior art date
Application number
IL239778A
Other languages
English (en)
Hebrew (he)
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL239778(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of IL239778A0 publication Critical patent/IL239778A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
IL239778A 2013-01-09 2015-07-05 Pharmaceutical preparations with controlled release of lorazepam IL239778A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (1)

Publication Number Publication Date
IL239778A0 true IL239778A0 (en) 2015-08-31

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239778A IL239778A0 (en) 2013-01-09 2015-07-05 Pharmaceutical preparations with controlled release of lorazepam

Country Status (16)

Country Link
EP (1) EP2943186A1 (ko)
JP (1) JP2016504391A (ko)
KR (1) KR20150127037A (ko)
CN (1) CN105188682A (ko)
AU (1) AU2014205356A1 (ko)
BR (1) BR112015016322A8 (ko)
CA (1) CA2897313A1 (ko)
CL (1) CL2015001921A1 (ko)
HK (1) HK1213803A1 (ko)
IL (1) IL239778A0 (ko)
MX (1) MX2015008757A (ko)
PE (1) PE20151431A1 (ko)
PH (1) PH12015501533A1 (ko)
RU (1) RU2015128914A (ko)
SG (1) SG11201505352RA (ko)
WO (1) WO2014110248A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008756A2 (pt) 2017-11-01 2020-10-13 Edgemont Pharmaceuticals, LLC Trust composições farmacêuticas orais de lorazepam resistentes a álcool

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (ko) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
AU2141202A (en) 2000-12-05 2002-06-18 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
KR100822519B1 (ko) * 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제

Also Published As

Publication number Publication date
CL2015001921A1 (es) 2015-12-18
BR112015016322A2 (pt) 2017-07-11
AU2014205356A1 (en) 2015-07-30
JP2016504391A (ja) 2016-02-12
BR112015016322A8 (pt) 2018-01-23
KR20150127037A (ko) 2015-11-16
PE20151431A1 (es) 2015-09-23
PH12015501533A1 (en) 2015-10-05
CN105188682A (zh) 2015-12-23
MX2015008757A (es) 2016-02-05
HK1213803A1 (zh) 2016-07-15
CA2897313A1 (en) 2014-07-17
SG11201505352RA (en) 2015-08-28
RU2015128914A (ru) 2017-02-14
EP2943186A1 (en) 2015-11-18
WO2014110248A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
IL280485A (en) Sustained-release pridopidine preparations
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
EP2991639A4 (en) PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
PL2981271T3 (pl) Zastosowania terapeutyczne empagliflozyny
HK1216839A1 (zh) 調整釋放製劑
EP2988595A4 (en) Gel formulations for the prolonged release of volatile compounds
ZA201505830B (en) Formulations of organc compounds
HK1213770A1 (zh) 勞拉西泮的緩釋製劑
HK1213803A1 (zh) 勞拉西泮的控釋製劑
PL3071575T3 (pl) Wytwarzanie normorfinanów